Literature DB >> 15070705

IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma.

Wendy Cozen1, Parkash S Gill, Sue Ann Ingles, Rizwan Masood, Otoniel Martínez-Maza, Myles G Cockburn, W James Gauderman, Malcolm C Pike, Leslie Bernstein, Bharat N Nathwani, Muhammad T Salam, Kathleen Lackerdas Danley, Wei Wang, Julia Gage, Susan Gundell-Miller, Thomas M Mack.   

Abstract

Identical twins of young adult Hodgkin lymphoma case subjects are much more likely to develop the disease compared with fraternal twins of case subjects, suggesting a genetic determinant. Interleukin 6 (IL-6) levels are increased in patients with Hodgkin lymphoma and are correlated with a poor prognosis. We hypothesized that a heritable abnormality in IL-6 regulation may predispose to young adult Hodgkin lymphoma. We obtained blood specimens from 88 young adult Hodgkin lymphoma case subjects and their twins as well as from 87 matched control subjects. IL-6 was measured from unstimulated peripheral blood mononuclear cell (PBMC) supernatant with enzyme-linked immunosorbent assays (ELISAs) and compared by using analysis of covariance. Unaffected identical twins of case subjects (surrogate case subjects) had a 87.8% higher IL-6 level compared with matched control subjects (mean difference, +483.7 pg/mL, P =.04). Analysis of the IL-6 174G>C promoter polymorphism genotypes showed that risk decreased with an increasing number of C alleles (P =.01). The CC (low secreting) genotype was associated with a decreased risk of young adult Hodgkin lymphoma relative to the GG (high secreting) genotype (odds ratio [OR] =.29; P =.03). Risk was decreased for both nodular sclerosis and other subtypes. Persons with genetically determined lower IL-6 levels may be less susceptible to young adult Hodgkin lymphoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15070705     DOI: 10.1182/blood-2003-08-2860

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  30 in total

1.  The impact of interleukin-6 promoter -597/-572/-174genotype on interleukin-6 production after lipopolysaccharide stimulation.

Authors:  M Müller-Steinhardt; B Ebel; C Härtel
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

2.  Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts.

Authors:  Hervé Ghesquières; Matthew J Maurer; Olivier Casasnovas; Stephen M Ansell; Beth R Larrabee; Eva Lech-Maranda; Anne J Novak; Anne-Laure Borrel; Susan L Slager; Pauline Brice; Cristine Allmer; Annie Brion; Steven C Ziesmer; Franck Morschhauser; Thomas M Habermann; Isabelle Gaillard; Brian K Link; Aspasia Stamatoullas; Christophe Fermé; Ahmet Dogan; William R Macon; Josée Audouin; James R Cerhan; Gilles Salles
Journal:  Cytokine       Date:  2013-09-03       Impact factor: 3.861

3.  Clinical relevance of IL-6 gene polymorphism in severely injured patients.

Authors:  Vasilije Jeremić; Tamara Alempijević; Srđan Mijatović; Ana Sijački; Sanja Dragašević; Sonja Pavlović; Biljana Miličić; Slobodan Krstić
Journal:  Bosn J Basic Med Sci       Date:  2014-05       Impact factor: 3.363

4.  A protective role for early oral exposures in the etiology of young adult Hodgkin lymphoma.

Authors:  Wendy Cozen; Ann S Hamilton; Peng Zhao; Muhammad T Salam; Dennis M Deapen; Bharat N Nathwani; Lawrence M Weiss; Thomas M Mack
Journal:  Blood       Date:  2009-09-08       Impact factor: 22.113

5.  Antibody titers against EBNA1 and EBNA2 in relation to Hodgkin lymphoma and history of infectious mononucleosis.

Authors:  Nancy E Mueller; Evelyne T Lennette; Kathryn Dupnik; Brenda M Birmann
Journal:  Int J Cancer       Date:  2011-08-30       Impact factor: 7.396

6.  Prognostic Significance of IL-6 in Hodgkin Lymphoma.

Authors:  Sainath Bhethanabhotla; Akash Tiwari; M C Sharma; Sreenivas Vishnubhatla; Sameer Bakhshi
Journal:  Indian J Pediatr       Date:  2019-03-04       Impact factor: 1.967

7.  Role of IL-6 -174(G/C) promoter polymorphism in the etiology of early-onset preeclampsia.

Authors:  Sabnavis Sowmya; Aruna Ramaiah; Pratibha Nallari; Akka Jyothy; Ananthapur Venkateshwari
Journal:  Inflamm Res       Date:  2015-04-28       Impact factor: 4.575

Review 8.  Harnessing the immune system to treat cancer.

Authors:  Nina Bhardwaj
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 9.  A cytokine-mediated link between innate immunity, inflammation, and cancer.

Authors:  Wan-Wan Lin; Michael Karin
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

10.  Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma.

Authors:  Robert J Biggar; Julia S Johansen; Karin Ekström Smedby; Klaus Rostgaard; Ellen T Chang; Hans-Olov Adami; Bengt Glimelius; Daniel Molin; Stephen Hamilton-Dutoit; Mads Melbye; Henrik Hjalgrim
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.